





Antonio Di Biagio

Durability nelle coorti italiane




Conflicts of interest

- I have participated in Advisory boards for ViiV Healthcare, Gilead Sciences, Janssen Cilag, Abbvie, MSD.
- I have received research grants from ViiV Healthcare and Gilead Sciences

Durabilità

durabilità s. f. [dal lat. tardo *durabilĭtas* -*atis*]. – L'essere durabile, qualità e condizione di ciò che può durare

Studio di Coorte



- Studia una coorte, ovvero un gruppo che sperimenta un dato evento, in un periodo selezionato, e lo studia ad intervalli di tempo.
- **Permette di rilevare i possibili fattori di rischio di una popolazione, ed il suo follow-up.**

Pratica Clinica




1 Quanto «dura» una ART:

- Naive
- Experienced
- HTE

2 Efficacia e Sicurezza



Alcuni esempi

Naive



«In our nonrandomized comparison, RPV was better tolerated, less toxic and showed longer durability than E without a significant difference in rates of discontinuation because of failures»

**«....in our real-life population,
we demonstrated high efficacy and
tolerability of all studied INSTI-based
regimens currently available in EU and
a lower risk of treatment failure in
those using DTG.**





«In ART-naïve patients with low viral loads and high CD4 counts, the risk of treatment failure was lower in those who started RPV-based vs. INSTIs-based regimens other than DTG-based ones».

Alcuni esempi


Experienced

**December 15,
2022;13:11**


«.....DTG+3TC demonstrated high virological efficacy but should be cautiously used in PLWH with a history of VF. In fact, a previous history of VF was associated with higher risk of VR and viral




Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA study.



«Reassuringly, the absolute risk of DT, even after 4 years of follow-up, remains low and below 9% of those treated with this drug»





«In our two-center cohort, we observed the long durability of RPV-STR together with preserved long-term efficacy of RPV-STR even in heterogeneous real-life populations. Given these data, RPV has the potential to be a drug for life when prescribed in adherence to current guidelines»





October 13, 2021





- **Switch to second ART regimens: toxicity (42.5%) and simplification (37.5%).**
- **Switch mostly involved the third drug (63.5%)**
- **(STR) as second treatment (30.6%).**
- **The median duration of second ART regimens was 9.2 months and the probabilities of treatment discontinuation at 12, 24, and 36 months were 21%, 35%, and 48.2%, respectively.**
- **STR formulations had a protective effect against second ART discontinuation.**
- **STR could improve second ART durability**



Durability of Mega ART in a large cohort of treatment experienced people living with HIV: Data from ARCA database



Cosa abbiamo da fare

- **Bictegravir**
- **Doravirina**
- **Long Acting**
- **.....**



Fondazione Icona
ITALIAN COHORT NAIVE ANTIRETROVIRALS
Conceived by Professor Mauro Moroni

CISAI

FONDAZIONE  **ASIA**